Company · founded 2007

Cognition Therapeutics (United States)

Pittsburgh, United States · cogrx.com

Manage this page

Citations, last 5 years: 230
Works, last 5 years: 40
h-index: 49
Scientists listed: 5
Grants since 2016: 35

Grants received

2023–2025 · research · Global Health

Addition Therapeutics, Inc. - to develop a gene therapy candidate for HIV and advance therapeutic applications in LMIC's

Cognition Therapeutics (United States) · funded by Bill and Melinda Gates Foundation

$4.3M

2021–2024 · research · R01

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies

Anthony O Caggiano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$10.8MDementia and Cognitive Impairment Research

2021–2024 · research · R01

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies

Anthony O Caggiano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$10.3MDementia and Cognitive Impairment Research

2021–2023 · grant · SB1

Human AME study of CT1812, a small molecule in phase 2 clinical trials for the treatment of Alzheimer's disease

Anthony O Caggiano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$1.6M

2021–2025 · research · R01

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies

Anthony O Caggiano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$8.5MDementia and Cognitive Impairment Research

2020–2027 · research · R01

Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months

Paul S. Aisen · Cognition Therapeutics (United States) · funded by National Institutes of Health

$13.1MAlzheimer's disease research and treatments

2020–2027 · research · R01

Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months

Paul S. Aisen · Cognition Therapeutics (United States) · funded by National Institutes of Health

$14.6MAlzheimer's disease research and treatments

2020–2021 · research · RF1

A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Subjects with Mild to Moderate Alzheimer's Disease

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$324.5kAlzheimer's disease research and treatments

2020–2025 · research · R01

Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months

Paul S. Aisen · Cognition Therapeutics (United States) · funded by National Institutes of Health

$24.5MAlzheimer's disease research and treatments

2020–2027 · research · R01

Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months

Paul S. Aisen · Cognition Therapeutics (United States) · funded by National Institutes of Health

$12M

2019–2023 · research · RF1

A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimerʼs Disease

Anthony O Caggiano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$3.3M

2019–2023 · research · RF1

A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimerʼs Disease

Anthony O Caggiano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$2.1M

2018–2021 · research · R01

A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$5.7MAlzheimer's disease research and treatments

2018–2021 · research · R01

A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$5.1MAlzheimer's disease research and treatments

2018–2024 · research · R01

A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease

Anthony O Caggiano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$5.8MAlzheimer's disease research and treatments

2018–2021 · research · R44

Mechanism of action of oligomer-displacing Alzheimer investigation drug, CT1812:Receptor interactions and signaling pathways

Nicholas John Izzo · Cognition Therapeutics (United States) · funded by National Institutes of Health

$729.2kPharmacological Receptor Mechanisms and Effects

2018–2024 · research · R01

A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimerʼs Disease

Anthony O Caggiano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$13.6MAlzheimer's disease research and treatments

2018–2019 · research · R44

Mechanism of action of oligomer-displacing Alzheimer investigation drug, CT1812:Receptor interactions and signaling pathways

Nicholas John Izzo · Cognition Therapeutics (United States) · funded by National Institutes of Health

$360.1kPharmacological Receptor Mechanisms and Effects

2018–2021 · research · R44

Mechanism of action of oligomer-displacing Alzheimer investigation drug, CT1812:Receptor interactions and signaling pathways

Nicholas John Izzo · Cognition Therapeutics (United States) · funded by National Institutes of Health

$699.3kPharmacological Receptor Mechanisms and Effects

2018–2024 · research · R01

A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease

Anthony O Caggiano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$278.6kAlzheimer's disease research and treatments

2017–2018 · research · R44

Structural variants of Abeta oligomer displacing small molecules

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$224.1kPharmacological Receptor Mechanisms and Effects

2017–2021 · research · RF1

A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Subjects with Mild to Moderate Alzheimer's Disease

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$4.1MAlzheimer's disease research and treatments

2017–2021 · research · RF1

A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Subjects with Mild to Moderate Alzheimer's Disease

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$340.6kAlzheimer's disease research and treatments

2017–2021 · research · R44

Structural variants of Abeta oligomer displacing small molecules

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$730.4kPharmacological Receptor Mechanisms and Effects

2017–2021 · research · RF1

A Pilot CSF Catheter Study to Evaluate the Effect of CT1812 Treatment on Aβ Oligomer Clearance into CSF in Subjects with Mild to Moderate Alzheimerʼs Disease

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$2.5M

2017–2020 · research · R44

Structural variants of Abeta oligomer displacing small molecules

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$734.4kPharmacological Receptor Mechanisms and Effects

2016–2020 · research · R44

Target Engagement Biomarkers for Alzheimer's Therapeutics

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$250k

2016–2019 · research · R44

Target Engagement Biomarkers for Alzheimer's Therapeutics

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$745.2k

2016–2020 · research · R44

Target Engagement Biomarkers for Alzheimer's Therapeutics

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$746.1k

2016–2017 · research · R44

Target Engagement Biomarkers for Alzheimer's Therapeutics

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$222k

2016–2018 · research · RF1

Phase 1 safety trial for CT1812, a novel small molecule therapeutic targeting a synaptic receptor for Abeta oligomers

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$2.4M

2016–2018 · research · R41

New piperazines effecting Abeta oligomer displacement from neuronal receptors

Nicholas John Izzo · Cognition Therapeutics (United States) · funded by National Institutes of Health

$224k

2016–2018 · research · RF1

Phase 1b first-in-patient safety trial for CT1812, a novel Alzheimer’s synaptic protection therapeutic

Susan M Catalano · Cognition Therapeutics (United States) · funded by National Institutes of Health

$2.4M

2015–2023 · research · R42

Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction

Nicholas John Izzo · Cognition Therapeutics (United States) · funded by National Institutes of Health

$1.1MPharmacological Receptor Mechanisms and Effects

2015–2020 · research · R42

Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction

Nicholas John Izzo · Cognition Therapeutics (United States) · funded by National Institutes of Health

$1.1MPharmacological Receptor Mechanisms and Effects